Skip to main content

Abstract : Urinary Incontinence & Endopeel

Successful treatment of urinary incontinence to the effort by the combined use of injections of Endopeel Products + PRP and placement of PDO threads.

Dr. Alain Tenenbaum (1), Mr. Mauro Tiziani (2),Dr. Ariel Luksenburg , Dr. Juan J. Barcia ,Dr. Roberto Sergio

Urine incontinence to stress is a major clinical problem affecting millions of women around the world. Loss of urine is related to increased intra-abdominal pressure and may have an anatomic cause (due to urethral hypermobility in which the urethral support elements are weakened or damaged) or intrinsic functional defect of the sphincter, Of both factors.
Taking into account the anatomo-functional bases of the pathology, we have developed a minimally invasive treatment to achieve toning the pelvic floor muscles, increasing the resistance of the urethra so that the intravesical pressure does not exceed the urethral during the exertions.

23 women between the ages of 38 and 62 with mild to moderate urinary stress incontinence with complete urodynamic studies were carefully selected and treated by placement of resorbable PDO (Polidioxanone) threads, vaginally, for urethral Longitudinal, along with injections of Endopeel + PRP in the periurethral muscles of the pelvic floor.

PDO strings are placed with the aid of a device specially designed for intra-vaginal approach, guided by a "fenestrated" speculum, developed to fit the course of the urethra (urethral protection) and the injections are applied with cannula type "Ballonet", of appropriate length, designed to reach precise anatomical levels.

Between 30 and 60 days post-treatment days, a complete cessation of urine loss to effort and normal urodynamic studies is observed.

The combined use of PDO threads + Endopeel + PRP  initially generates a pelvic floor tension and then localized and controlled fibrosis that elevates the sphincter unit and produces functional recovery without side effects.

The treatment described is a new economic alternative, fast acting, with no side effects and effective in 87% and partially effective in 13%* of the cases studied until the moment of stress urinary incontinence.
* With significant partial improvements with 2 treatments performed. Upcoming treatments

(1) Specialist in facial plastic surgery- Switzerland- Inventor of Endopeel- e mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
(2) Molecular Biologist-Switzerland- Co Inventor of Endopeel- e mail: This email address is being protected from spambots. You need JavaScript enabled to view it.